Patent application number | Description | Published |
20090304683 | Soluble Fragments of The Sars-Cov Spike Glycoprotein - The invention relates to the spike protein from the virus (SARS-CoV) that is etiologically linked to severe acute respiratory syndrome (SARS); polypeptides and peptide fragments of the spike protein; nucleic acid segments and constructs that encode the spike protein, polypeptides and peptide fragments of the spike protein, and coupled proteins that include the spike protein or a portion thereof; peptidomimetics; vaccines; methods for vaccination and treatment of severe acute respiratory syndrome; antibodies; aptamers; and kits containing immunological compositions, or antibodies (or aptamers) that bind to the spike protein. | 12-10-2009 |
20100055033 | ANTIBODY COMPOSITIONS AND METHODS FOR TREATMENT OF NEOPLASTIC DISEASE - Antibody compositions and methods for treatment of neoplastic disease in a mammalian subject are provided. Methods of diagnosing cancer in a mammalian subject are also provided. | 03-04-2010 |
20100316641 | ENGINEERED ANTIBODY CONSTANT DOMAIN MOLECULES - Described herein are engineered antibody constant domain molecules, such as CH2 or CH3 domain molecules, comprising at least one mutation, or comprising at least one complementarity determining region (CDR), or a functional fragment thereof, engrafted in a loop region of the CH2 domain. The CH2 domain molecules described herein are small, stable, soluble, exhibit little to no toxicity and are capable of binding antigen. | 12-16-2010 |
20100317837 | IDENTIFICATION OF NOVEL BROADLY CROSS-REACTIVE NEUTRALIZING HUMAN MONOCLONAL ANTIBODIES USING SEQUENTIAL ANTIGEN PANNING OF PHAGE DISPLAY LIBRARIES - The present invention provides a method of identifying novel broadly crossreactive neutralizing monoclonal antibodies using sequential antigen panning of phage display libraries, antibodies obtained in accordance with such a method, as well as fusion proteins and conjugates comprising same, and related isolated or purified nucleic acid molecules, vectors, host cells, compositions, and methods of use to inhibit an infection, reduce the severity of an infection, treat an infection, and inhibit cancer. | 12-16-2010 |
20110008358 | HUMAN MONOCLONAL ANTIBODIES THAT SPECIFICALLY BIND IGF-II - Disclosed herein are isolated monoclonal human antibodies that specifically binds insulin-like growth factor II (IGF-II) with an equilibrium dissociation constant (K | 01-13-2011 |
20110020344 | HUMAN MONOCLONAL ANTIBODIES SPECIFIC FOR CD22 - Disclosed herein are isolated human monoclonal antibodies that specifically bind human CD22 with a dissociation constant (K | 01-27-2011 |
20110020361 | HUMAN ANTI-MESOTHELIN MONOCLONAL ANTIBODIES - Disclosed herein are isolated human monoclonal antibodies that specifically bind human mesothelin with a binding affinity of about 25 nM or less. Nucleic acids encoding these antibodies, expression vectors including these nucleic acid molecules, and isolated host cells that express the nucleic acid molecules are also disclosed. The antibodies can be used to detect human mesothelin in a sample. Methods of diagnosing cancer, or confirming a diagnosis of cancer, are disclosed herein that utilize these antibodies. Methods of treating a subject with cancer are also disclosed. | 01-27-2011 |
20110104163 | ANTI-HIV DOMAIN ANTIBODIES AND METHOD OF MAKING AND USING SAME - The invention provides single domain antibodies and derivatives thereof that bind antigens of interest, which are stable, soluble, and do not tend to aggregate. The invention also provides methods for constructing a dAb library and methods for screening dAb libraries to identify the dAb of the invention. The invention also provide methods of treating or preventing conditions by antigen neutralization by administering the dAbs of the invention. | 05-05-2011 |
20120114656 | Human Monoclonal Antibodies Protective Against Bubonic Plague - In this application are described fully human monoclonal antibodies which specifically recognize F1 or V antigen of | 05-10-2012 |
20120195897 | HUMAN DOMAIN ANTIBODIES AGAINST COMPONENTS OF THE HUMAN INSULIN-LIKE GROWTH FACTOR (IGF) SYSTEM - The invention provides antibodies or antibody fragments that bind to insulin-like growth factor (IGF) 1 receptor (IGF-1R) or IGF-2, as well as method of using the antibodies for inhibiting the IGF-mediated signaling pathway, inhibiting IGF-1R signaling, and treating cancer. The invention also provides a method of detecting the presence of IGF-1R or IGF-2 in a sample using the inventive antibodies and antibody fragments. | 08-02-2012 |
20130108636 | HIGH-AFFINITY FULLY FUNCTIONAL SOLUBLE SINGLE-DOMAIN HUMAN CD4, ANTIBODIES, AND RELATED FUSION PROTEINS | 05-02-2013 |
20130177570 | ANTI-HUMAN FOLATE RECEPTOR BETA ANTIBODIES AND METHODS OF USE - Human anti-human folate receptor beta antibodies and antigen-binding fragments thereof are described, as well as methods of using such antibodies and fragments to treat inflammatory disorders or cancers expressing cell surface FRĪ². | 07-11-2013 |
20130189247 | Multimeric Proteins Comprising Immunoglobulin Constant Domains - The present invention relate to small binding proteins comprising two or more protein domains derived from a CH2 domain or CH2-like domain of an immunoglobulin in which the CH2 domains have been altered to recognize one or more target proteins and, in some embodiments, retain, or have modified, certain secondary effector functions. | 07-25-2013 |
20130315921 | HUMAN MONOCLONAL ANTIBODIES SPECIFIC FOR CD22 - Disclosed herein are isolated human monoclonal antibodies that specifically bind human CD22 with a dissociation constant (K | 11-28-2013 |
20140023645 | ENGINEERED ANTIBODY CONSTANT DOMAIN MOLECULES - Described herein are engineered antibody constant domain molecules, such as CH2 or CH3 domain molecules, comprising at least one mutation, or comprising at least one complementarity determining region (CDR), or a functional fragment thereof, engrafted in a loop region of the CH2 domain. The CH2 domain molecules described herein are small, stable, soluble, exhibit little to no toxicity and are capable of binding antigen. | 01-23-2014 |
20140044714 | HUMAN MONOCLONAL ANTIBODIES SPECIFIC FOR GLYPICAN-3 AND USE THEREOF - Described herein is the identification of human monoclonal antibodies that bind GPC3 or heparan sulfate (HS) chains on GPC3 with high affinity. The antibodies described herein are capable of inhibiting HCC cell growth and migration. Provided are human monoclonal antibodies specific for GPC3 or HS chains on GPC3, including immunoglobulin molecules, such as IgG antibodies, as well as antibody fragments, such as single-domain VH antibodies or single chain variable fragments (scFv). Further provided are compositions including the antibodies that bind GPC3 or HS chains on GPC3, nucleic acid molecules encoding these antibodies, expression vectors comprising the nucleic acids, and isolated host cells that express the nucleic acids. Methods of treating cancer and/or inhibiting tumor growth or metastasis are also provided. Further provided are methods of detecting cancer in a subject and confirming a diagnosis of cancer in a subject. | 02-13-2014 |
20140044720 | HUMAN MONOCLONAL ANTIBODIES THAT BIND INSULIN-LIKE GROWTH FACTOR (IGF) I AND II - Disclosed herein are human monoclonal antibodies that specifically bind both IGF-I and IGF-II with picomolar affinity and potently inhibit the IGF-IR signal transduction function. These antibodies are active in both an IgG and a scFv format. Bispecific forms of these antibodies are also disclosed. Nucleic acids encoding these antibodies, vectors including these nucleic acids, and host cells transformed with these vectors are also disclosed herein. Also disclosed are pharmaceutical compositions including these antibodies. Methods are provided for treating a subject with cancer and for inhibiting phosphorylation of the insulin-like growth factor-I receptor. Methods are also provided for diagnosing cancer. | 02-13-2014 |
20140271646 | MONOSPECIFIC AND BISPECIFIC HUMAN MONOCLONAL ANTIBODIES TARGETING INSULIN-LIKE GROWTH FACTOR II (IGF-II) - Monoclonal antibodies (mAbs), antigen binding fragments and engineered antibody domains (eAds) that specifically bind IGF-II are disclosed herein. In some embodiments, these mAbs and eAds are included in a bispecific mAb. In some embodiments, the bispecific antibody specifically binds two different epitopes of IGF-II. Methods of using these mAbs, antigen binding fragments, and eAds, bispecific antibodies, and nucleic acids encoding these mAbs, antigen binding fragments, and eAds, bispecific antibodies are also disclosed. | 09-18-2014 |
20150050278 | SOLUBLE ENGINEERED MONOMERIC FC - Fc domains and CH3 domains are disclosed that bind the neonatal Fc (FcRn) receptor and are at least 99% monomeric. Monomeric Fc domain molecules and CH3 domain molecules are disclosed herein that include a monomeric Fc domain or a monomeric CH3 domain and an effector molecule. In some embodiments, the monomeric Fc or monomeric CH3 domain include amino acid substitutions and/or CDR insertions in the beta strands such that they specifically bind an antigen. Methods for using these monomeric Fc domains, monomeric CH3 domains, monomeric Fc domain molecules and CH3 domain molecules are also provided. | 02-19-2015 |